Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Chief Executive Officer and a Director
On July 22, 2021, Thomas Griffin submitted his resignation from his positions as
Chief Executive Officer and as a member of the Board of Directors (the "Board")
of Medifirst Solutions, Inc. (the "Company"), effective immediately (the "CEO
Resignation"). Mr. Griffin did not resign as a result of any disagreement with
the Company on any matter relating to the Company's operations, policies or
practices. A copy of Mr. Griffin's letter of resignation is attached hereto as
Exhibits 17.1 to this Current Report on Form 8-K.
Appointment of Chief Executive Officer
On July 23, 2021, in connection with the CEO Resignation, the Board appointed
Mr. Jonathan Cross as Interim Chief Executive Officer and the sole member of the
Board, effective immediately (the "CEO Appointment").
Mr. Cross' compensation will be determined at a later time.
Mr. Cross is a Managing Director at Shefford Capital Partners, LLC, a New York
based Private Equity firm, and is a seasoned investor with over 33 years of
experience in principal investing, domestic and cross boarder M&A and corporate
restructuring.
There is no arrangement or understanding between Mr. Cross and any other persons
pursuant to which Mr. Cross was selected as an officer and director. There are
no family relationships between Mr. Cross and any director, executive officer or
person nominated or chosen by the Company to become a director or executive
officer of the Company within the meaning of Item 401(d) of Regulation S-K under
the U.S. Securities Act of 1933 ("Regulation S-K"). Since the beginning of the
Company's last fiscal year, the Company has not engaged in any transaction in
which Mr. Cross had a direct or indirect material interest within the meaning of
Item 404(a) of Regulation S-K.
The above description of the Letter of Resignation does not purport to be
complete and is qualified in its entirety by the full text of such document,
filed herewith as Exhibit 17.1.
Item 9.01 Financial Statements and Exhibits.
d) Exhibits.
Exhibit No. Description
17.1 Letter of Resignation from
1© Edgar Online, source Glimpses
MEDIFIRST SOLUTIONS, INC 
